LENALIDOMIDE PHARMACOKINETICS IN COMBINATION WITH IDARUBION AND CYTARABINE IN PATIENTS WITH ACUTE MYELOID LEUKEMIA.

被引：0
|
作者：
Jiang, Y. [1 ]
Wang, J. [2 ]
Walker, A. [3 ]
Li, X. [4 ]
Drake, A. [2 ]
Schaaf, L. [2 ]
Byrd, J. [3 ]
Marcucci, G. [3 ]
Grever, M. [3 ]
Blum, W. [3 ]
Phelps, M. [1 ]
机构：
[1] Ohio State Univ, Coll Pharm, Columbus, OH 43210 USA
[2] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA
[3] Ohio State Univ, Dept Med, Div Hematol, Columbus, OH 43210 USA
[4] Ohio State Univ, Ctr Biostat, Columbus, OH 43210 USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2013年 / 93卷
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：S66 / S67
页数：2
相关论文
共 50 条
  • [21] Treatment of elderly acute myeloid leukemia (AML) patients with the combination of mitoxantrone and cytarabine (MAC).
    Marinakis, T
    Galanopoulos, AG
    Zomas, A
    Michalis, E
    Gortzolidis, G
    Tsakiridou, A
    Xanthopoulos, V
    Theodoropoulos, G
    Goumakou, H
    Georgiakaki, M
    Grigoraki, V
    Anagnostopoulos, NI
    BLOOD, 2005, 106 (11) : 235B - 235B
  • [22] A phase 1 trial evaluating thioridazine in combination with cytarabine in patients with acute myeloid leukemia
    Aslostovar, Lili
    Boyd, Allison L.
    Almakadi, Mohammed
    Collins, Tony J.
    Leong, Darryl P.
    Tirona, Rommel G.
    Kim, Richard B.
    Julian, Jim A.
    Xenocostas, Anargyros
    Leber, Brian
    Levine, Mark N.
    Foley, Ronan
    Bhatia, Mickie
    BLOOD ADVANCES, 2018, 2 (15) : 1935 - 1945
  • [23] Acute myeloid leukemia. Analysis of 114 patients
    Triantafilo, Nicolas
    Sarmiento, Mauricio
    Campbell, James
    Rojas, Patricio
    Jose Garcia, Maria
    Sandoval, Vicente
    Bertin, Pablo
    Ocqueteau, Mauricio
    Concepcion Risueno, Maria
    Rodriguez, Isabel
    Galleguillos, Mauricio
    REVISTA MEDICA DE CHILE, 2022, 150 (05) : 643 - 649
  • [24] Sequential azacitidine plus lenalidomide combination for elderly patients with untreated acute myeloid leukemia
    Pollyea, Daniel A.
    Zehnder, James
    Coutre, Steve
    Gotlib, Jason R.
    Gallegos, Leonel
    Abdel-Wahab, Omar
    Greenberg, Peter
    Zhang, Bing
    Liedtke, Michaela
    Berube, Caroline
    Levine, Ross
    Mitchell, Beverly S.
    Medeiros, Bruno C.
    HAEMATOLOGICA, 2013, 98 (04) : 591 - 596
  • [25] Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
    Solans, Belen P.
    Fleury, Angele
    Freiwald, Matthias
    Fritsch, Holger
    Haug, Karin
    Troconiz, Inaki F.
    CLINICAL PHARMACOKINETICS, 2018, 57 (03) : 379 - 392
  • [26] Population Pharmacokinetics of Volasertib Administered in Patients with Acute Myeloid Leukaemia as a Single Agent or in Combination with Cytarabine
    Belén P. Solans
    Angèle Fleury
    Matthias Freiwald
    Holger Fritsch
    Karin Haug
    Iñaki F. Trocóniz
    Clinical Pharmacokinetics, 2018, 57 : 379 - 392
  • [27] A phase I study of lenalidomide plus chemotherapy with mitoxantrone, etoposide, and cytarabine for the reinduction of patients with acute myeloid leukemia
    DeAngelo, Daniel J.
    Brunner, Andrew M.
    Werner, Lillian
    Avigan, David
    Fathi, Amir T.
    Sperling, Adam S.
    Washington, Abigail
    Stroopinsky, Dina
    Rosenblatt, Jacalyn
    McMasters, Malgorzata
    Luptakova, Katarina
    Wadleigh, Martha
    Steensma, David P.
    Hobbs, Gabriela S.
    Attar, Eyal C.
    Amrein, Philip C.
    Ebert, Benjamin L.
    Stone, Richard M.
    Ballen, Karen K.
    AMERICAN JOURNAL OF HEMATOLOGY, 2018, 93 (02) : 254 - 261
  • [28] Activity of the Multikinase Inhibitor Sorafenib in Combination With Cytarabine in Acute Myeloid Leukemia
    Hu, Shuiying
    Niu, Hongmei
    Inaba, Hiroto
    Orwick, Shelley
    Rose, Charles
    Panetta, John C.
    Yang, Shengping
    Pounds, Stanley
    Fan, Yiping
    Calabrese, Christopher
    Rehg, Jerold E.
    Campana, Dario
    Rubnitz, Jeffrey E.
    Baker, Sharyn D.
    JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2011, 103 (11) : 893 - 905
  • [29] Final results of a phase II pharmacokinetic/pharmacodynamic (PK/PD) study of combination voreloxin and cytarabine in patients with relapsed or refractory acute myeloid leukemia.
    Roboz, G. J.
    Lancet, J. E.
    Cripe, L. D.
    Kashani, F. Ravandi
    List, A. F.
    Fox, J. A.
    Michelson, G.
    Karp, J. E.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [30] AS1411 IN COMBINATION WITH CYTARABINE IN RELAPSED AND REFRACTORY ACUTE MYELOID LEUKEMIA
    Stuart, K.
    Stockerl-Goldstein, K.
    Cooper, M.
    Devetten, M.
    Herzig, R.
    Medeiros, B.
    Schiller, G.
    Wei, A.
    Acton, G.
    Rizzieri, D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 336 - 336
12345